How Analysts Rated Emergent BioSolutions Inc. (NYSE:EBS) Last Week?

June 14, 2018 - By Hannah Black

Emergent BioSolutions Inc. (NYSE:EBS) LogoInvestors sentiment decreased to 1.77 in 2018 Q1. Its down 0.25, from 2.02 in 2017Q4. It fall, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported.
9,526 are held by Regions Fincl. Old Mutual (Uk) Ltd accumulated 25,807 shares. Earnest Partners Limited Co has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Yorktown Management And Research holds 0.13% or 8,600 shares in its portfolio. Invesco Limited has 0.02% invested in Emergent BioSolutions Inc. (NYSE:EBS). Renaissance Llc has 1.87M shares. Fdx Inc owns 0.04% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 24,786 shares. Gemmer Asset Mngmt Ltd Limited Liability Company holds 0% or 90 shares. Piedmont Inv Limited Liability Company stated it has 7,598 shares. The Massachusetts-based Putnam Invs Lc has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). Arizona State Retirement System accumulated 55,338 shares or 0.03% of the stock. Ls Ltd Llc invested in 3,848 shares. Art Advsr Limited Liability Corporation reported 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). Sg Americas Securities Ltd Liability Corp holds 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 3,243 shares. State Of Alaska Department Of Revenue invested 0.01% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS).

Since January 2, 2018, it had 0 buys, and 11 sales for $4.28 million activity. Abdun-Nabi Daniel sold $1.05 million worth of Emergent BioSolutions Inc. (NYSE:EBS) on Tuesday, January 2. Havey Adam sold $308,574 worth of stock or 5,842 shares. Another trade for 8,375 shares valued at $436,876 was made by Hauer Jerome M on Tuesday, June 5. $389,126 worth of Emergent BioSolutions Inc. (NYSE:EBS) was sold by Richard Ronald on Wednesday, June 6. On Monday, June 11 the insider JOULWAN GEORGE A sold $264,448.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 5 analysts covering Emergent BioSolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent BioSolutions had 5 analyst reports since January 24, 2018 according to SRatingsIntel. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Buy” rating by Singular Research on Tuesday, February 27. The stock has “Buy” rating by Cantor Fitzgerald on Monday, June 11. The rating was downgraded by Wells Fargo to “Hold” on Tuesday, April 24. Below is a list of Emergent BioSolutions Inc. (NYSE:EBS) latest ratings and price target changes.

13/06/2018 Broker: Argus Research Rating: Buy New Target: $62 Initiates Coverage On
11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $62.0000 Initiate
24/04/2018 Broker: Wells Fargo Rating: Hold New Target: $56.0000 Downgrade
27/02/2018 Broker: Singular Research Old Rating: Buy New Rating: Buy Old Target: $45 New Target: $60 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $55 Initiates Coverage On

The stock increased 0.27% or $0.15 during the last trading session, reaching $55.68. About 209,388 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 14, 2017 and is uptrending. It has outperformed by 52.96% the S&P500.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.77 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 32.64 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” on June 13, 2018, also Globenewswire.com with their article: “Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility” published on June 07, 2018, Streetinsider.com published: “Cantor Fitzgerald Starts Emergent BioSolutions (EBS) at Overweight” on June 11, 2018. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Benzinga.com and their article: “Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth” published on June 13, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: June 12, 2018.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.